Skip to main content
NCBI home page
Journal of Clinical Microbiology logoLink to Journal of Clinical Microbiology
. 1994 Jan;32(1):220–223. doi: 10.1128/jcm.32.1.220-223.1994

Utility of quantitative enzyme immunoassay reactivity for predicting human immunodeficiency virus seropositivity in low- and high-prevalence populations.

X Hou 1, P L Breese 1, J M Douglas Jr 1
PMCID: PMC263002  PMID: 8126185

Abstract

To assess the utility of quantitative enzyme immunoassay (EIA) reactivity for predicting human immunodeficiency virus seropositivity, we evaluated 22,823 serum samples from homo- and bisexual men, heterosexual intravenous drug users, and other heterosexuals with initial screening by EIA, retesting of reactive samples in duplicate, and confirmatory Western blot (immunoblot) testing. Quantitative EIA reactivity was determined by a mean of the optical density ratio of the three assays performed for each reactive specimen. A total of 1,773 samples (7.8%) were repeatedly reactive, and 1,747 (7.7%) were confirmed Western blot positive. All 26 EIA-reactive-Western blot-negative samples had low-level EIA reactivity (ratio < 2.2), while most (86%) of the Western blot-positive samples had high-level reactivity (ratio, > 3.0). The positive predictive value for samples with moderate-to-high-level EIA reactivity (ratio, > 2.2) was 100% for all risk groups. These results support the value of quantitative EIA reactivity in predicting human immunodeficiency virus seropositivity and suggest that confirmatory testing of specimens with high-level reactivity is not necessary in all situations.

Full text

PDF
220

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Burke D. S., Brundage J. F., Redfield R. R., Damato J. J., Schable C. A., Putman P., Visintine R., Kim H. I. Measurement of the false positive rate in a screening program for human immunodeficiency virus infections. N Engl J Med. 1988 Oct 13;319(15):961–964. doi: 10.1056/NEJM198810133191501. [DOI] [PubMed] [Google Scholar]
  2. Carlson J. R., Bryant M. L., Hinrichs S. H., Yamamoto J. K., Levy N. B., Yee J., Higgins J., Levine A. M., Holland P., Gardner M. B. AIDS serology testing in low- and high-risk groups. JAMA. 1985 Jun 21;253(23):3405–3408. [PubMed] [Google Scholar]
  3. Cleary P. D., Barry M. J., Mayer K. H., Brandt A. M., Gostin L., Fineberg H. V. Compulsory premarital screening for the human immunodeficiency virus. Technical and public health considerations. JAMA. 1987 Oct 2;258(13):1757–1762. [PubMed] [Google Scholar]
  4. Davey R. T., Jr, Lane H. C. Laboratory methods in the diagnosis and prognostic staging of infection with human immunodeficiency virus type 1. Rev Infect Dis. 1990 Sep-Oct;12(5):912–930. doi: 10.1093/clinids/12.5.912. [DOI] [PubMed] [Google Scholar]
  5. Goedert J. J. Testing for human immunodeficiency virus. Ann Intern Med. 1986 Oct;105(4):609–610. doi: 10.7326/0003-4819-105-4-609. [DOI] [PubMed] [Google Scholar]
  6. Handsfield H. H., Wandell M., Goldstein L., Shriver K. Screening and diagnostic performance of enzyme immunoassay for antibody to lymphadenopathy-associated virus. J Clin Microbiol. 1987 May;25(5):879–884. doi: 10.1128/jcm.25.5.879-884.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Lepine D. G., Neumann P. W., Frenette S. L., O'Shaughnessy M. V. Evaluation of a human immunodeficiency virus test algorithm utilizing a recombinant protein enzyme immunoassay. J Clin Microbiol. 1990 Jun;28(6):1169–1171. doi: 10.1128/jcm.28.6.1169-1171.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. MacDonald K. L., Jackson J. B., Bowman R. J., Polesky H. F., Rhame F. S., Balfour H. H., Jr, Osterholm M. T. Performance characteristics of serologic tests for human immunodeficiency virus type 1 (HIV-1) antibody among Minnesota blood donors. Public health and clinical implications. Ann Intern Med. 1989 Apr 15;110(8):617–621. doi: 10.7326/0003-4819-110-8-617. [DOI] [PubMed] [Google Scholar]
  9. Meyer K. B., Pauker S. G. Screening for HIV: can we afford the false positive rate? N Engl J Med. 1987 Jul 23;317(4):238–241. doi: 10.1056/NEJM198707233170410. [DOI] [PubMed] [Google Scholar]
  10. Mortimer P. P. The fallibility of HIV western blot. Lancet. 1991 Feb 2;337(8736):286–287. doi: 10.1016/0140-6736(91)90884-r. [DOI] [PubMed] [Google Scholar]
  11. N'Galy B., Bertozzi S., Ryder R. W. Obstacles to the optimal management of HIV infection/AIDS in Africa. J Acquir Immune Defic Syndr. 1990;3(4):430–437. [PubMed] [Google Scholar]
  12. Nishanian P., Taylor J. M., Korns E., Detels R., Saah A., Fahey J. L. Significance of quantitative enzyme-linked immunosorbent assay (ELISA) results in evaluation of three ELISAs and Western blot tests for detection of antibodies to human immunodeficiency virus in a high-risk population. J Clin Microbiol. 1987 Feb;25(2):395–400. doi: 10.1128/jcm.25.2.395-400.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Schwartz J. S., Dans P. E., Kinosian B. P. Human immunodeficiency virus test evaluation, performance, and use. Proposals to make good tests better. JAMA. 1988 May 6;259(17):2574–2579. [PubMed] [Google Scholar]
  14. Sivak S. L., Wormser G. P. Predictive value of a screening test for antibodies to HTLV-III. Am J Clin Pathol. 1986 Jun;85(6):700–703. doi: 10.1093/ajcp/85.6.700. [DOI] [PubMed] [Google Scholar]
  15. Spielberg F. A., Kabeya C. M., Quinn T. C., Ryder R. W., Kifuani N. K., Harris J., Bender T. R., Heyward W. L., Tam M. R., Auditore-Hargreaves K. Performance and cost-effectiveness of a dual rapid assay system for screening and confirmation of human immunodeficiency virus type 1 seropositivity. J Clin Microbiol. 1990 Feb;28(2):303–306. doi: 10.1128/jcm.28.2.303-306.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Steckelberg J. M., Cockerill F. R., 3rd Serologic testing for human immunodeficiency virus antibodies. Mayo Clin Proc. 1988 Apr;63(4):373–380. doi: 10.1016/s0025-6196(12)64860-5. [DOI] [PubMed] [Google Scholar]
  17. Ward J. W., Grindon A. J., Feorino P. M., Schable C., Parvin M., Allen J. R. Laboratory and epidemiologic evaluation of an enzyme immunoassay for antibodies to HTLV-III. JAMA. 1986 Jul 18;256(3):357–361. [PubMed] [Google Scholar]
  18. Weiss S. H., Goedert J. J., Sarngadharan M. G., Bodner A. J., Gallo R. C., Blattner W. A. Screening test for HTLV-III (AIDS agent) antibodies. Specificity, sensitivity, and applications. JAMA. 1985 Jan 11;253(2):221–225. [PubMed] [Google Scholar]

Articles from Journal of Clinical Microbiology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES